Security assessments indicated that gastrointestinal adverse events, principally nausea and diarrhea, had been dose-dependent but generally moderate and transient. These results set up the therapeutic window and informed dose variety for subsequent Phase 3 trials.Renal safety has become similarly reassuring. Across Section 1–three trials, therapy